Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01726270 · ClinicalTrials.gov registry record · Phase 2
An 8-week, Open-label, Uncontrolled Study of Tamsulosin 0.4mg in Men With Bothersome Urinary Symptoms
A Phase 2 study of Lower Urinary Tract Symptoms, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 689
- Enrollment target
- 18
- Study locations
NCT01726270 is a Phase 2 study of Lower Urinary Tract Symptoms that has completed, run by Boehringer Ingelheim. The registered enrollment target is 689 participants, roughly in line with the 718-participant average among 21 other Lower Urinary Tract Symptoms trials with a reported enrollment target. The trial reports 18 study locations across 8 states.
The verdict
NCT01726270, a Phase 2 study of Lower Urinary Tract Symptoms, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 689 participants
- Enrollment target
- 18
- Study locations
Study Summary
Multicenter trial conducted in Pharmacy retail centers
Conditions Studied
Interventions
- DRUG tamsulosin
Study Locations (18)
Minnesota
- Boehringer Ingelheim Investigational Site - Anoka
- Boehringer Ingelheim Investigational Site - Elk River
- Boehringer Ingelheim Investigational Site - Fridley
- Boehringer Ingelheim Investigational Site - Roseville
- Boehringer Ingelheim Investigational Site - Saint Francis
Utah
- Boehringer Ingelheim Investigational Site - Bountiful
- Boehringer Ingelheim Investigational Site - Layton
- Boehringer Ingelheim Investigational Site - Salt Lake City
- Boehringer Ingelheim Investigational Site - Syracuse
California
- Boehringer Ingelheim Investigational Site - Encino
- Boehringer Ingelheim Investigational Site - Garden Grove
- Boehringer Ingelheim Investigational Site - La Habra
Texas
- Boehringer Ingelheim Investigational Site - Longview
- Boehringer Ingelheim Investigational Site - Tyler
Alabama
- Boehringer Ingelheim Investigational Site - Hoover
Arizona
- Boehringer Ingelheim Investigational Site - Mesa
New Mexico
- Boehringer Ingelheim Investigational Site - Albuquerque
Virginia
- Boehringer Ingelheim Investigational Site - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 689 participants |
| Start Date | 2012-11 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01726270
The ClinicalTrials.gov registry entry for NCT01726270 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 689 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 718-participant average among 21 other Lower Urinary Tract Symptoms trials with a reported enrollment target. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lower Urinary Tract Symptoms appearing as the primary indexed condition, and to 1 intervention - of which tamsulosin is the first listed.
NCT01726270 reports 18 study locations spanning 8 distinct geographic areas - top geographies include Minnesota, Utah, California.
Frequently Asked Questions
What is clinical trial NCT01726270 about?
NCT01726270 is a clinical study titled "An 8-week, Open-label, Uncontrolled Study of Tamsulosin 0.4mg in Men With Bothersome Urinary Symptoms". Multicenter trial conducted in Pharmacy retail centers
What is the current status of trial NCT01726270?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 689 participants. The study started on 2012-11. Estimated completion is 2013-03.
What conditions does trial NCT01726270 study?
This clinical trial studies the following conditions: Lower Urinary Tract Symptoms.
What interventions are being tested in trial NCT01726270?
The interventions under investigation include: tamsulosin (DRUG).
Who is sponsoring clinical trial NCT01726270?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01726270 being conducted?
This trial has 18 study locations across Alabama, Arizona, California, Minnesota, New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lower Urinary Tract Symptoms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing MitoQ on Lower Urinary Tract Symptoms in Older Women With Metabolic Syndrome
RECRUITING · Phase 2
-
Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction
COMPLETED · Phase 2
-
Impact of Probiotics on Urinary Symptoms in Spinal Cord Injury SCI and SB
COMPLETED · Phase 2
-
Combined Behavioral and Drug Treatment of Overactive Bladder in Men
COMPLETED · Phase 2
-
US Imaging for the Assessment of LUTS
RECRUITING
-
Preoperative Pelvic Floor Physical Therapy to Minimize Stress Urinary Incontinence After Holmium Laser Enucleation of the Prostate
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.